Breast Cancer Recurrence Risk Calculator

Q: What factors determine breast cancer recurrence risk?

Breast cancer recurrence risk is determined by multiple clinical and pathological factors working together. The most significant factors include tumor size at diagnosis, lymph node involvement, histological grade, hormone receptor status (ER/PR), HER2 status, and Ki-67 proliferation index. Larger tumors, positive lymph nodes, higher grade, and negative hormone receptors all increase recurrence ris

Q: How does hormone receptor status affect recurrence risk?

Hormone receptor status, particularly estrogen receptor (ER) and progesterone receptor (PR) status, significantly influences both recurrence risk and treatment options. ER-positive tumors (about 70-80% of breast cancers) generally have lower recurrence rates because they respond to endocrine therapy such as tamoxifen or aromatase inhibitors. These treatments can reduce recurrence by approximately

Q: What role does HER2 status play in breast cancer recurrence?

HER2 (Human Epidermal Growth Factor Receptor 2) is overexpressed in approximately 15-20% of breast cancers and historically was associated with aggressive disease and higher recurrence rates. However, the development of HER2-targeted therapies like trastuzumab (Herceptin) has dramatically improved outcomes for HER2-positive patients. Without targeted therapy, HER2-positive tumors have significantl

Q: How does tumor size affect the likelihood of cancer returning?

Tumor size at diagnosis is one of the strongest independent predictors of breast cancer recurrence. Tumors smaller than 1 centimeter (T1a/T1b) without lymph node involvement have recurrence rates generally below 10% at ten years. Tumors between 1-2 centimeters have moderate recurrence risk around 15-25%, while tumors between 2-5 centimeters have substantially higher risk of 25-40%. Tumors larger t

Q: What is Ki-67 and why does it matter for recurrence risk assessment?

Ki-67 is a protein marker that indicates how quickly cancer cells are dividing (proliferating). It is measured as a percentage of tumor cells showing active cell division. A Ki-67 score below 14% is generally considered low proliferation, 14-20% is intermediate, and above 20% is high proliferation. Higher Ki-67 values are associated with more aggressive tumors and increased recurrence risk. Ki-67

Q: When does breast cancer recurrence typically occur?

The timing of breast cancer recurrence varies by molecular subtype and is clinically important for surveillance planning. ER-negative and HER2-positive tumors tend to recur earlier, with the highest recurrence rates in the first two to three years after diagnosis, declining sharply after five years. ER-positive tumors have a different pattern with a steadier, ongoing rate of recurrence that extend

Use our free Breast cancer recurrence risk Calculator to get personalized health results. Based on validated medical formulas and clinical guidelines.

Share this calculator

X Facebook LinkedIn

Formula

NPI = (Tumor Size cm x 0.2) + Node Stage + Grade | Risk adjusted for ER, HER2, Ki-67, and age

The Nottingham Prognostic Index forms the foundation, combining tumor size (in centimeters multiplied by 0.2), lymph node stage (1-3), and histological grade (1-3). Additional risk modifiers include estrogen receptor status, HER2 overexpression, Ki-67 proliferation index, and patient age. The composite risk estimate reflects ten-year recurrence probability.

Worked Examples

Example 1: Low Risk ER-Positive Case

Problem: A 60-year-old woman with a 15mm grade 1 ER-positive, HER2-negative tumor, no lymph nodes involved, Ki-67 of 10%. What is her recurrence risk?

Solution: NPI = (1.5 x 0.2) + 0 + 1 = 1.3\nTumor size contribution: 8 (15mm, 10-20mm range)\nNode contribution: 0 (no nodes)\nGrade contribution: 0 (grade 1)\nER status: -5 (positive)\nHER2: 0 (negative)\nKi-67: 0 (below 14%)\nAge factor: -3 (over 70)\nBase risk adjusted: ~10%

Result: 5-Year Recurrence Risk: ~10% (Low Risk) | Endocrine therapy alone likely sufficient

Example 2: High Risk Triple Assessment

Problem: A 45-year-old woman with a 35mm grade 3 ER-negative, HER2-positive tumor, 3 positive lymph nodes, Ki-67 of 40%. What is her recurrence risk?

Solution: NPI = (3.5 x 0.2) + 3 + 3 = 6.7\nTumor size: 18 (20-50mm range)\nNodes: 24 (3 nodes x 8)\nGrade: 14 (grade 3)\nER negative: +10\nHER2 positive: +8\nKi-67 >20%: +8\nAge <50: no extra penalty\nBase risk adjusted: ~72%

Result: 5-Year Recurrence Risk: ~72% (Very High Risk) | Multi-agent chemotherapy + HER2-targeted therapy recommended

Frequently Asked Questions

What factors determine breast cancer recurrence risk?

Breast cancer recurrence risk is determined by multiple clinical and pathological factors working together. The most significant factors include tumor size at diagnosis, lymph node involvement, histological grade, hormone receptor status (ER/PR), HER2 status, and Ki-67 proliferation index. Larger tumors, positive lymph nodes, higher grade, and negative hormone receptors all increase recurrence risk. Additionally, patient age, lymphovascular invasion, and surgical margins play important roles. Genomic assays like Oncotype DX and MammaPrint provide additional molecular-level risk stratification that goes beyond traditional clinical factors to help guide treatment decisions.

How does hormone receptor status affect recurrence risk?

Hormone receptor status, particularly estrogen receptor (ER) and progesterone receptor (PR) status, significantly influences both recurrence risk and treatment options. ER-positive tumors (about 70-80% of breast cancers) generally have lower recurrence rates because they respond to endocrine therapy such as tamoxifen or aromatase inhibitors. These treatments can reduce recurrence by approximately 40-50% over ten years. ER-negative tumors tend to be more aggressive and have higher early recurrence rates, particularly in the first three to five years after diagnosis. However, ER-positive cancers have a unique pattern of late recurrence extending beyond ten years, which is why extended endocrine therapy may be recommended.

What role does HER2 status play in breast cancer recurrence?

HER2 (Human Epidermal Growth Factor Receptor 2) is overexpressed in approximately 15-20% of breast cancers and historically was associated with aggressive disease and higher recurrence rates. However, the development of HER2-targeted therapies like trastuzumab (Herceptin) has dramatically improved outcomes for HER2-positive patients. Without targeted therapy, HER2-positive tumors have significantly higher recurrence rates compared to HER2-negative tumors. With trastuzumab-based treatment, recurrence risk is reduced by approximately 35-40%. Newer agents including pertuzumab, T-DM1, and tucatinib provide additional options for reducing recurrence, making HER2-positive breast cancer one of the most treatable subtypes.

How does tumor size affect the likelihood of cancer returning?

Tumor size at diagnosis is one of the strongest independent predictors of breast cancer recurrence. Tumors smaller than 1 centimeter (T1a/T1b) without lymph node involvement have recurrence rates generally below 10% at ten years. Tumors between 1-2 centimeters have moderate recurrence risk around 15-25%, while tumors between 2-5 centimeters have substantially higher risk of 25-40%. Tumors larger than 5 centimeters carry the highest risk, often exceeding 40% recurrence at ten years without systemic therapy. Tumor size also correlates with lymph node involvement, meaning larger tumors are more likely to have spread to regional lymph nodes, compounding the risk further.

What is Ki-67 and why does it matter for recurrence risk assessment?

Ki-67 is a protein marker that indicates how quickly cancer cells are dividing (proliferating). It is measured as a percentage of tumor cells showing active cell division. A Ki-67 score below 14% is generally considered low proliferation, 14-20% is intermediate, and above 20% is high proliferation. Higher Ki-67 values are associated with more aggressive tumors and increased recurrence risk. Ki-67 is particularly useful in distinguishing Luminal A (low Ki-67) from Luminal B (high Ki-67) molecular subtypes in hormone receptor-positive breast cancer. This distinction affects treatment decisions, as Luminal B tumors may benefit more from chemotherapy in addition to endocrine therapy.

When does breast cancer recurrence typically occur?

The timing of breast cancer recurrence varies by molecular subtype and is clinically important for surveillance planning. ER-negative and HER2-positive tumors tend to recur earlier, with the highest recurrence rates in the first two to three years after diagnosis, declining sharply after five years. ER-positive tumors have a different pattern with a steadier, ongoing rate of recurrence that extends well beyond five years, with approximately half of all ER-positive recurrences occurring after five years. This late recurrence risk is why extended endocrine therapy (beyond five years) is recommended for many ER-positive patients. Triple-negative breast cancer has the highest early recurrence rate but very few recurrences after five years.